Search Results

You are looking at 1 - 10 of 2,311 items for :

Clear All
Full access

Philip E. Johnson, George Dahlman, Kirby Eng, Rekha Garg, Scott Gottlieb, James M. Hoffman, Peyton Howell, Mohammad Jahanzeb, Shirley Johnson, Emily Mackler, Mark Rubino, Brenda Sarokhan, F. Marc Stewart, Tim Tyler, Julie M. Vose, Sharon Weinstein, Edward C. Li and Jessica DeMartino

particularly important issue for oncology and the NCCN. A disproportionate number of drugs with complex REMS are used in patients with cancer or hematologic disorders. REMS policies and process within oncology may act as a model for other clinical areas. A

Full access

Peter F. Coccia, Alberto S. Pappo, Lynda Beaupin, Virginia F. Borges, Scott C. Borinstein, Rashmi Chugh, Shira Dinner, Jeanelle Folbrecht, A. Lindsay Frazier, Robert Goldsby, Alexandra Gubin, Robert Hayashi, Mary S. Huang, Michael P. Link, John A. Livingston, Yousif Matloub, Frederick Millard, Kevin C. Oeffinger, Diane Puccetti, Damon Reed, Steven Robinson, Abby R. Rosenberg, Tara Sanft, Holly L. Spraker-Perlman, Margaret von Mehren, Daniel S. Wechsler, Kimberly F. Whelan, Nicholas Yeager, Lisa A. Gurski and Dorothy A. Shead

assessment has been reported for AYA patients. There are less evidence-based data to guide the treatment of AYA patients. AYA NCCN Clinical Practice Guidelines in Oncology : Adolescent and Young Adult Oncology, Version 2.2018 Version 2.2018, 10

Full access

Peter F. Coccia, Alberto S. Pappo, Jessica Altman, Smita Bhatia, Scott C. Borinstein, Joseph Flynn, A. Lindsay Frazier, Suzanne George, Robert Goldsby, Robert Hayashi, Mary S. Huang, Rebecca H. Johnson, Lynda Kwon Beaupin, Michael P. Link, Kevin C. Oeffinger, Kathleen M. Orr, Damon Reed, Holly L. Spraker, Deborah A. Thomas, Margaret von Mehren, Daniel S. Wechsler, Kimberly F. Whelan, Brad Zebrack, Dorothy A. Shead and Hema Sundar

to: Integrate into professional practice the updates to NCCN Guidelines for Adolescent and Young Adult Oncology Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Adolescent and Young Adult Oncology

Full access

Arti Hurria, Tanya Wildes, Sarah L. Blair, Ilene S. Browner, Harvey Jay Cohen, Mollie deShazo, Efrat Dotan, Barish H. Edil, Martine Extermann, Apar Kishor P. Ganti, Holly M. Holmes, Reshma Jagsi, Mohana B. Karlekar, Nancy L. Keating, Beatriz Korc-Grodzicki, June M. McKoy, Bruno C. Medeiros, Ewa Mrozek, Tracey O’Connor, Hope S. Rugo, Randall W. Rupper, Rebecca A. Silliman, Derek L. Stirewalt, William P. Tew, Louise C. Walter, Alva B. Weir III, Mary Anne Bergman and Hema Sundar

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Senior Adult Oncology address specific issues related to the management of cancer in older adults, including screening and comprehensive geriatric assessment (CGA), assessing the risks

Full access

Arti Hurria, Ilene S. Browner, Harvey Jay Cohen, Crystal S. Denlinger, Mollie deShazo, Martine Extermann, Apar Kishor P. Ganti, Jimmie C. Holland, Holly M. Holmes, Mohana B. Karlekar, Nancy L. Keating, June McKoy, Bruno C. Medeiros, Ewa Mrozek, Tracey O’Connor, Stephen H. Petersdorf, Hope S. Rugo, Rebecca A. Silliman, William P. Tew, Louise C. Walter, Alva B. Weir III and Tanya Wildes

Guidelines in Oncology for Senior Adult Oncology NCCN Categories of Evidence and Consensus Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Category 2A: Based upon lower-level evidence

Full access

Jane M. Quigley

, it is more important than ever to know how to “ask the data the right questions” to obtain relevant and valid results. Physician-level data are ubiquitous. Oncology patients, providers, clinical research organizations, the federal government, and

Full access

Alyson Haslam, Jennifer Gill and Vinay Prasad

Background Noninferiority (NI) trials are being conducted more frequently, and oncology is numerically 1 of the top 3 medical disciplines for published NI trials. 1 These trials can help to establish treatment options that are less expensive, less

Full access

Peter F. Coccia, Jessica Altman, Smita Bhatia, Scott C. Borinstein, Joseph Flynn, Suzanne George, Robert Goldsby, Robert Hayashi, Mary S. Huang, Rebecca H. Johnson, Lynda Kwon Beaupin, Michael P. Link, Kevin C. Oeffinger, Kathleen M. Orr, Alberto S. Pappo, Damon Reed, Holly L. Spraker, Deborah A. Thomas, Margaret von Mehren, Daniel S. Wechsler, Kimberly F. Whelan, Bradley J. Zebrack, Hema Sundar and Dorothy A. Shead

cancer by age group and sex in the AYA population. 10 NCCN Clinical Practice Guidelines in Oncology : Adolescent and Young Adult Oncology, Version 1.2012 Version 1.2012, 02-21-12 ©2012 National Comprehensive Cancer Network, Inc. All rights

Full access

Pamala A. Pawloski, Gabriel A. Brooks, Matthew E. Nielsen and Barbara A. Olson-Bullis

implementation of a CDS system is a major undertaking, considering the vast amount of clinical data and its variability, availability, and structure across facilities. Clinical oncology is a dynamic, multidimensional healthcare specialty with complex decision

Full access

Rowena N. Schwartz, Kirby J. Eng, Deborah A. Frieze, Tracy K. Gosselin, Niesha Griffith, Amy Hatfield Seung, Jennifer M. Hinkel, Philip E. Johnson, Shirley A. Johnson, Edward C. Li, Audrea Hotsko Szabatura and Michael K. Wong

The use of specialty pharmacy is expanding in oncology pharmacy practice. 1 Specialty pharmacies provide one channel for distribution of drugs and biologics that, from the payor perspective, creates economies of scale and streamlines delivery of